A single TCRα-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire

Journal of Immunology

Volumn 184, Issue 3, 2010, Pages 1617-1629

  Liang, Xiaoling ^a   Weigand, Luise U ^a   Schuster, Ingrid G ^a   Eppinger, Elfriede ^a   Van Der Griendt, Judith C ^a   Schub, Andrea ^a,b   Leisegang, Matthias ^d   Sommermeyer, Daniel ^d   Anderl, Florian ^c   Han, Yanyan ^a   Ellwart, Joachim ^a   Moosmann, Andreas ^a,b   Busch, Dirk H ^a,c,f   Uckert, Wolfgang ^d,e   Peschel, Christian ^a   Krackhardt, Angela M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; ALLOANTIGEN; EPITOPE; HER2 PROTEIN, HUMAN; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT;

ANTIGEN SPECIFICITY; ARTICLE; BASE MISPAIRING; CANCER CELL CULTURE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL STRAIN MCF 7; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CELL CLONE; CELL LINE; CELL STRAIN K 562; CLINICAL TRIAL; HYBRID CELL; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; MOLECULAR GENETICS; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; HYBRID CELLS; IMMUNODOMINANT EPITOPES; ISOANTIGENS; JURKAT CELLS; K562 CELLS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS;

EID: 77949325014     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902155     Document Type: Article

References (58)

1. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
2. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
3. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
4. Sadovnikova, E., and H. J. Stauss. 1996. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class Imolecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93: 13114-13118.
5. Xue, S. A., L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, and H. Stauss. 2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106: 3062-3067. (Pubitemid 41565901)
6. Altmann, D. M., D. C. Douek, A. J. Frater, C. M. Hetherington, H. Inoko, and J. I. Elliott. 1995. The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J. Exp. Med. 181: 867-875.
7. Schumacher, T. N. 2002. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2: 512-519.
8. Schuster, I. G., D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nössner, et al. 2007. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 110: 2931-2939.
9. Shepard, H. M., C. M. Brdlik, and H. Schreiber. 2008. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 118: 3574-3581.
10. Bühring, H. J., I. Sures, B. Jallal, F. U. Weiss, F. W. Busch, W. D. Ludwig, R. Handgretinger, H. D. Waller, and A. Ullrich. 1995. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 86: 1916-1923.
11. Anderson, K., P. Cresswell, M. Gammon, J. Hermes, A. Williamson, and H. Zweerink. 1991. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J. Exp. Med. 174: 489-492.
12. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443-446.
13. Heemskerk, M. H., M. Hoogeboom, R. A. de Paus, M. G. Kester, M. A. van der Hoorn, E. Goulmy, R. Willemze, and J. H. Falkenburg. 2003. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved a joining region. Blood 102: 3530-3540.
14. Conrad, H., K. Gebhard, H. Krönig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard. 2008. CTLs directed against HER2 specifically cross-react with HER3 and HER4. J. Immunol. 180: 8135-8145.
15. Falk, K., O. Rötzschke, M. Takiguchi, B. Grahovac, V. Gnau, S. Stevanović, G. Jung, and H. G. Rammensee. 1994. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 40: 238-241.
16. Rongcun, Y., F. Salazar-Onfray, J. Charo, K. J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. 1999. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163: 1037-1044.
17. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181: 2109-2117.
18. Morrison, J., J. Elvin, F. Latron, F. Gotch, R. Moots, J. L. Strominger, and A. McMichael. 1992. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur. J. Immunol. 22: 903-907.
19. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527-534.
20. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157: 2539-2548.
21. Diamond, D. J., J. York, J. Y. Sun, C. L. Wright, and S. J. Forman. 1997. Development of a candidate HLA Ap0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751-1767.
22. Busch, D. H., I. M. Pilip, S. Vijh, and E. G. Pamer. 1998. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 8: 353-362.
23. Knabel, M., T. J. Franz, M. Schiemann, A. Wulf, B. Villmow, B. Schmidt, H. Bernhard, H. Wagner, and D. H. Busch. 2002. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8: 631-637.
24. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10: 485-492.
25. Roth, M. E., M. J. Lacy, L. K. McNeil, and D. M. Kranz. 1989. Analysis of T cell receptor transcripts using the polymerase chain reaction. Biotechniques 7: 746-754.
26. Lefranc, M. P. 2003. IMGT databases, web resources and tools for immunoglobulin and T cell receptor sequence analysis, http://imgt.cines.fr. Leukemia 17: 260-266.
27. Sommermeyer, D., J. Neudorfer, M. Weinhold, M. Leisegang, B. Engels, E. Noessner, M. H. Heemskerk, J. Charo, D. J. Schendel, T. Blankenstein, et al. 2006. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36: 3052-3059.
28. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
29. Scholten, K. B., D. Kramer, E. W. Kueter, M. Graf, T. Schoedl, C. J. Meijer, M. W. Schreurs, and E. Hooijberg. 2006. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119: 135-145.
30. Jorritsma, A., R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. Schumacher, and J. B. Haanen. 2007. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110: 3564-3572. (Pubitemid 350159623)
31. Leisegang, M., B. Engels, P. Meyerhuber, E. Kieback, D. Sommermeyer, S. A. Xue, S. Reuss, H. Stauss, and W. Uckert. 2008. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J. Mol. Med. 86: 573-583.
32. Schub, A., I. G. Schuster, W. Hammerschmidt, and A. Moosmann. 2009. CMV-specific TCR-transgenic T cells for immunotherapy. J. Immunol. 183: 6819-6830.
33. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171: 3287-3295.
34. Sensi, M., S. Salvi, C. Castelli, C. Maccalli, A. Mazzocchi, R. Mortarini, G. Nicolini, M. Herlyn, G. Parmiani, and A. Anichini. 1993. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J. Exp. Med. 178: 1231-1246.
35. Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, et al. 2003. Prevalent role of TCR α-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170: 5103-5109.
36. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
37. Cohen, C. J., Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.
38. Voss, R. H., R. A. Willemsen, J. Kuball, M. Grabowski, R. Engel, R. S. Intan, P. Guillaume, P. Romero, C. Huber, and M. Theobald. 2008. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J. Immunol. 180: 391-401.
39. Sebestyén, Z., E. Schooten, T. Sals, I. Zaldivar, E. San José, B. Alarcón, S. Bobisse, A. Rosato, J. Szöllosi, J. W. Gratama, et al. 2008. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and β chains following gene transfer. J. Immunol. 180: 7736-7746.
40. Hausmann, S., W. E. Biddison, K. J. Smith, Y. H. Ding, D. N. Garboczi, U. Utz, D. C. Wiley, and K. W. Wucherpfennig. 1999. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J. Immunol. 162: 5389-5397. (Pubitemid 29307147)
41. Felix, N. J., D. L. Donermeyer, S. Horvath, J. J. Walters, M. L. Gross, A. Suri, and P. M. Allen. 2007. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat. Immunol. 8: 388-397.
42. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961-3968.
43. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74: 929-937. (Pubitemid 23270612)
44. Nicholls, S., K. P. Piper, F. Mohammed, T. R. Dafforn, S. Tenzer, M. Salim, P. Mahendra, C. Craddock, P. van Endert, H. Schild, et al. 2009. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc. Natl. Acad. Sci. USA 106: 3889-3894.
45. Leone, F., E. Perissinotto, G. Cavalloni, V. Fonsato, S. Bruno, N. Surrenti, D. Hong, A. Capaldi, M. Geuna, W. Piacibello, and M. Aglietta. 2003. Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J. Leukoc. Biol. 74: 593-601.
46. Kieback, E., J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert. 2008. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. USA 105: 623-628.
47. González, P. A., L. J. Carreño, D. Coombs, J. E. Mora, E. Palmieri, B. Goldstein, S. G. Nathenson, and A. M. Kalergis. 2005. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc. Natl. Acad. Sci. USA 102: 4824-4829.
48. Kuhns, J. J., M. A. Batalia, S. Yan, and E. J. Collins. 1999. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J. Biol. Chem. 274: 36422-36427.
49. Weidanz, J. A., T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Internati, W. H. Hildebrand, and J. Lustgarten. 2006. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J. Immunol. 177: 5088-5097.
50. Vertuani, S., C. Triulzi, A. K. Roos, J. Charo, H. Norell, F. Lemonnier, P. Pisa, B. Seliger, and R. Kiessling. 2009. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol. Immunother. 58: 653-664.
51. Yokosuka, T., K. Takase, M. Suzuki, Y. Nakagawa, S. Taki, H. Takahashi, T. Fujisawa, H. Arase, and T. Saito. 2002. Predominant role of T cell receptor (TCR)-α chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J. Exp. Med. 195: 991-1001.
52. Blackman, M., J. Yagüe, R. Kubo, D. Gay, C. Coleclough, E. Palmer, J. Kappler, and P. Marrack. 1986. The T cell repertoire may be biased in favor of MHC recognition. Cell 47: 349-357. (Pubitemid 17210149)
53. Huseby, E. S., J. White, F. Crawford, T. Vass, D. Becker, C. Pinilla, P. Marrack, and J. W. Kappler. 2005. How the T cell repertoire becomes peptide and MHC specific. Cell 122: 247-260.
54. Maynard, J., K. Petersson, D. H. Wilson, E. J. Adams, S. E. Blondelle, M. J. Boulanger, D. B. Wilson, and K. C. Garcia. 2005. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 22: 81-92. (Pubitemid 40143453)
55. Feng, D., C. J. Bond, L. K. Ely, J. Maynard, and K. C. Garcia. 2007. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat. Immunol. 8: 975-983.
56. Dai, S., E. S. Huseby, K. Rubtsova, J. Scott-Browne, F. Crawford, W. A. Macdonald, P. Marrack, and J. W. Kappler. 2008. Crossreactive T Cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Immunity 28: 324-334.
57. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62.
58. Chervin, A. S., J. D. Stone, P. D. Holler, A. Bai, J. Chen, H. N. Eisen, and D. M. Kranz. 2009. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J. Immunol. 183: 1166-1178.